Robbins LLP Files Class Action Against Sarepta Therapeutics Over ELEVIDYS Deaths.
Robbins LLP has filed a securities class action on behalf of investors who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025.
The lawsuit centers on alleged misrepresentations related to the safety of ELEVIDYS, Sarepta’s gene therapy for Duchenne muscular dystrophy.
According to the complaint, Sarepta failed to disclose serious risks associated with ELEVIDYS, including:
-
Reports of life-threatening side effects during clinical trials;
-
Inadequate monitoring protocols that failed to catch early warning signs;
-
The potential for regulatory delays and trial suspensions resulting from adverse events.
Sarepta’s stock dropped sharply after a series of safety disclosures related to ELEVIDYS. On March 18, 2025, the company announced a patient had died following treatment, sending shares down over 27% to close at $73.54.
Less than three months later, on June 15, a second death, this time due to acute liver failure, prompted Sarepta to pause shipments and dosing in certain trials.
The stock plunged again, closing at $20.91 after a 42% drop. Then, on June 24, the FDA confirmed it was investigating liver failure risks tied to ELEVIDYS, and the stock fell further to $17.46 the next day.
Investors who incurred losses during this period may be eligible to join the lawsuit. The deadline to apply for lead plaintiff is August 25, 2025, though participation is not required to benefit from any potential recovery.
To learn more or discuss your legal options:
-
Call (800) 350-6003
-
Email attorney Aaron Dumas, Jr.
-
Or submit a form at RobbinsLLP.com
All cases are handled on a contingency fee basis, clients pay no legal fees unless a recovery is obtained.
Sarepta Therapeutics, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing genetic medicines for rare neuromuscular diseases. Best known for its work in Duchenne muscular dystrophy (DMD), Sarepta leverages RNA technology, gene therapy, and gene editing platforms to advance treatments from research through commercialization. The company operates globally and is led by President and CEO Doug Ingram.
Robbins LLP is a nationally recognized law firm focused on shareholder and consumer rights. The firm represents investors in securities fraud, corporate misconduct, and fiduciary duty cases, helping to recover losses and improve corporate governance. With a proven track record and commitment to accountability, Robbins LLP continues to be a trusted advocate for investor protection.
More Articles from Lawyer Monthly
-
Florida Criminal Charges: A Legal Guide to Arrest and Defense
-
Florida’s “Alligator Alcatraz”: Legal and Human Rights Challenges
